Aegis Awarded Russian Patent for Non-Invasive Delivery of Triptan Anti-Migraine Drugs
September 01, 2015 06:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Sep 1, 2015) - Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of...
Aegis Therapeutics Awarded Third Patent for Metered Nasal Spray Parathyroid Hormone (PTH) Peptide Drug Formulations
August 27, 2015 06:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Aug 27, 2015) - Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 9,114,069 titled "Antibacterial Compositions for Drug Administration"...
Aegis Awarded Chinese and Japanese Patents for Non-Invasive Delivery of Triptan Anti-Migraine Drugs
August 11, 2015 06:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Aug 11, 2015) - Aegis Therapeutics LLC announced today that it has been awarded foreign patents providing expanded coverage for non-invasive delivery of triptan...
Aegis Awarded U.S. Patent No. 8,927,497 for Non-Invasive Delivery of Anti-Seizure Drugs
February 18, 2015 08:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Feb 18, 2015) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,927,497 providing broad coverage for non-invasive delivery of...
Aegis Awarded Patent for Intranasal Administration of Active Agents to the Central Nervous System
November 12, 2014 05:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Nov 12, 2014) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,883,728, providing for highly efficient delivery of drugs to the...
Aegis Awarded 2nd Patent for Monoclonal Antibody Formulations That Avoid Oxidative Damage Due to Polysorbate Surfactants
October 07, 2014 04:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Oct 7, 2014) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,846,044, dramatically broadening its patent franchise to cover all...
First Non-Injectable GLP-1 Analog for Type-2 Diabetes
August 05, 2014 05:01 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Aug 5, 2014) - Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal...
Aegis Awarded US Patent for Stable "Shirt-Pocket" Insulin Suitable for Metered Nasal Spray or Injection
July 08, 2014 05:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Jul 8, 2014) - Aegis Therapeutics LLC announced today that it has been awarded its U.S. Patent No. 8,772,231 providing dramatically stabilized insulin formulations...
Aegis Intravail(R) Technology Enhances Oral Bioavailability of Tableted OTC Drugs
March 12, 2014 12:06 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Mar 12, 2014) - Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving...
Aegis Awarded Its First Patent for Oral Delivery of Nucleotide-Based Drugs With High Bioavailability
February 05, 2014 04:00 ET
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - Feb 5, 2014) - Aegis Therapeutics LLC announced today that it has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon Aegis'...